Sulfadoxine

Overview

A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

Indication

Sulfadoxine is used in combination with pyrimethamine for the treatment or prevention of malaria. It can also be used to treat various infections in livestock as well. Sulfadoxine and pyrimethamine is indicated for the treatment of Plasmodium falciparum malaria in those patients in whom chloroquine resistance is suspected.

Associated Conditions

Malaria
Malaria caused by Plasmodium falciparum
Acute, uncomplicated Malaria caused by plasmodium falciparum

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition	2025/03/11	NCT06869850	Not Applicable	Not yet recruiting	Washington University School of Medicine
Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet	2024/07/26	NCT06522763	Phase 1	Not yet recruiting	Swiss Pharma Nigeria Limited
Eggs for Gut Health	2023/08/21	NCT06002438	Not Applicable	Completed	Washington University School of Medicine
Comparing Chemoprevention Drugs for School-based Malaria Control	2023/08/07	NCT05980156	Phase 4	Completed	University of Maryland, Baltimore
Improving Cognition and Gestational Duration With Targeted Nutrition	2023/07/17	NCT05949190	Not Applicable	Recruiting	Washington University School of Medicine
Perennial Malaria Chemoprevention (PMC) in Cameroon	2023/06/05	NCT05889052	N/A	Active, not recruiting	London School of Hygiene and Tropical Medicine
Perennial Malaria Chemoprevention (PMC) in Côte D'Ivoire	2023/05/12	NCT05856357	N/A	Active, not recruiting	London School of Hygiene and Tropical Medicine
Chemoprevention Efficacy Study in Burkina Faso	2022/07/28	NCT05478954	Phase 4	Active, not recruiting	Malaria Consortium
Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan	2022/07/25	NCT05471544	Phase 3	Active, not recruiting	Malaria Consortium
Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy	2022/06/22	NCT05426434	Phase 3	Active, not recruiting	Menzies School of Health Research

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
FANSIDAR TABLETS	Hoffmann-La Roche Limited	00692719	Tablet - Oral	500 MG	12/31/1989

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access